Shortening Timelines for Upstream Bioprocessing of Protein-based Therapeutics
Posted on December 15, 2015
By: Dr Jincai Li, Executive Director, Biologics Process Development, Wuxi AppTec, China.
li_jincai@wuxiapptec.com
Sarah Wang, Technical Director, Bioprocess Solutions, Sartorius, China.
Xuyu.wang@sartorius-stedim.com
Dr Barney Zoro, ambr15 product manager, Sartorius Stedim Biotech, UK.
barney.zoro@sartorius-stedim.com
Joerg Weyand, Field Marketing Manager Fermentation Asia, Sartorius Stedim Biotech, Germany.
Joerg.Weyand@Sartorius-Stedim.com
The world-wide use of protein-based therapeutics has increased dramatically in the past 15 years. As a result, finding more cost-effective and efficient methods of improving upstream bioprocess production is a high priority for many biopharmaceutical firms. One strategy to improve upstream productio...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
automated bioreactor mimics, automated micro, biologic drugs including monoclonal antibodies, bioprocess development, bioprocessing models, cell line, Clone Screening, cost-effective and efficient methods, Dr Jincai Li, fusion proteins, increase upstream cell culture productivity, large scale bioreactors, mAbs, manufacturing timescales, mini bioreactor platforms, optimise media, optimising media, Shortening Timelines, therapeutic enzymes, Upstream Bioprocessing of Protein-based Therapeutics, upstream production, Wuxi apptec
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy